XNAS · Healthcare · Biotechnology
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.16 | -0.13 | +18.75% | $70.9M | ✅ Beat | +5.95% | -1.09% | — |
| 2026-02-05 | Q4 2025 | -0.19 | -0.09 | +52.63% | $71.7M | ✅ Beat | +6.25% | -5.65% | -9.78% |
| 2025-11-05 |
| Q3 2025 |
| -0.15 |
| -0.15 |
| +0.00% |
| $60.2M |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -0.24 | -0.17 | +29.17% | $58.9M | ✅ Beat | +8.60% | +14.57% | +17.83% |
| 2025-02-11 | Q4 2024 | -0.24 | -0.23 | +4.17% | $47.5M | ✅ Beat | -3.21% | +6.03% | -8.08% |
| 2024-11-07 | Q3 2024 | -0.29 | -0.22 | +24.14% | $46.4M | ✅ Beat | +3.37% | -0.89% | +14.39% |
| 2024-08-01 | Q2 2024 | -0.33 | -0.31 | +6.06% | $43.2M | ✅ Beat | -3.37% | -1.12% | +0.90% |
| 2024-05-07 | Q1 2024 | -0.34 | -0.33 | +2.94% | $41.9M | ✅ Beat | +2.25% | +27.33% | +25.40% |
Showing last 8 quarters.